Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ilaria Serio is active.

Publication


Featured researches published by Ilaria Serio.


Journal of Viral Hepatitis | 2017

Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older

F. Conti; Stefano Brillanti; Federica Buonfiglioli; Ranka Vukotic; Maria Cristina Morelli; Claudine Lalanne; Marco Massari; Francesco Giuseppe Foschi; Veronica Bernabucci; Ilaria Serio; Gian Maria Prati; Elisa Negri; Lorenzo Badia; Paolo Caraceni; Paolo Muratori; Giovanni Vitale; A. Porro; Marta Morotti; G. Mazzella; Pietro Andreone

The availability of direct‐acting antiviral agents (DAA) regimens has expanded the pool of patients eligible for treatment. However, data on the virologic response and tolerability of DAAs in elderly patients are lacking. We evaluated the efficacy and safety of DAAs in patients with advanced fibrosis/cirrhosis in real‐life practice with the focus on those aged ≥65 years. Between January and December 2015, all consecutive patients with HCV‐related advanced fibrosis/cirrhosis treated with DAA at eleven tertiary referral centres in Emilia Romagna (Italy) were enrolled. Regimen choice was based on viral genotype and stage of disease, according to guidelines. The primary end point was sustained virologic response 12 weeks after the end of treatment (SVR12). Overall, 282 of 556 (50.7%) patients evaluated were elderly, most of them with cirrhosis. Antiviral therapy was stopped prematurely in four (1.4%) patients. Two patients, both with cirrhosis, died during treatment due to worsening of liver/renal function. SVR12 was achieved by 94.7% and was comparable to that obtained in patients aged <65 (P=.074). Similar data were also reported in subgroup of patients aged ≥75 years. All patients with advanced fibrosis achieved virologic response. SVR12 was 80.8% in Child‐Pugh‐Turcotte (CTP)‐B cirrhosis and 95.4% in CTP‐A (P=.013). According to genotype, the SVR12 was achieved in 172 of 181 (95%) with genotype 1b cirrhosis and in 44 of 48 (91.7%) with genotype 2 cirrhosis. In conclusions, in a real‐world setting, DAAs are safe and effective in elderly patients with HCV‐related advanced fibrosis/cirrhosis, but SVR12 is lower with worsening CTP class.


Digestive and Liver Disease | 2017

Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study

Fabio Piscaglia; Veronica Salvatore; Lorenzo Mulazzani; Vito Cantisani; Antonio Colecchia; Roberto Di Donato; Cristina Felicani; Alessia Ferrarini; N. Gamal; Valentina Grasso; Giovanni Marasco; Elena Mazzotta; F. Ravaioli; Giacomo Ruggieri; Ilaria Serio; Joules Fabrice Sitouok Nkamgho; Carla Serra; Davide Festi; Cosima Schiavone; Luigi Bolondi

BACKGROUND AND AIMS Whether Fibroscan thresholds can be immediately adopted for none, some or all other shear wave elastography techniques has not been tested. The aim of the present study was to test the concordance of the findings obtained from 7 of the most recent ultrasound elastography machines with respect to Fibroscan. METHODS Sixteen hepatitis C virus-related patients with fibrosis ≥2 and having reliable results at Fibroscan were investigated in two intercostal spaces using 7 different elastography machines. Coefficients of both precision (an index of data dispersion) and accuracy (an index of bias correction factors expressing different magnitudes of changes in comparison to the reference) were calculated. RESULTS Median stiffness values differed among the different machines as did coefficients of both precision (range 0.54-0.72) and accuracy (range 0.28-0.87). When the average of the measurements of two intercostal spaces was considered, coefficients of precision significantly increased with all machines (range 0.72-0.90) whereas of accuracy improved more scatteredly and by a smaller degree (range 0.40-0.99). CONCLUSIONS The present results showed only moderate concordance of the majority of elastography machines with the Fibroscan results, preventing the possibility of the immediate universal adoption of Fibroscan thresholds for defining liver fibrosis staging for all new machines.


Autoimmunity Reviews | 2017

Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients ☆

Pierre-Edouard Gavand; Ilaria Serio; Laurent Arnaud; Nathalie Costedoat-Chalumeau; Julien Carvelli; Antoine Dossier; Olivier Hinschberger; Luc Mouthon; Véronique Le Guern; Anne-Sophie Korganow; Vincent Poindron; Clément Gourguechon; Christian Lavigne; F. Maurier; Guylaine Labro; Marie Heymonet; Matthieu Artifoni; Amélie Brabant Viau; Cristophe Deligny; Thomas Sené; Louis Terriou; Jean Sibilia; Alexis Mathian; Coralie Bloch-Queyrat; Claire Larroche; Zahir Amoura; Thierry Martin

OBJECTIVES Macrophage activation syndrome (MAS) is a life-threatening hyperinflammatory syndrome that can occur during systemic lupus erythematosus (SLE). Data on MAS in adult SLE patients are very limited. The aim of this study is to describe the clinical characteristics, laboratory findings, treatments, and outcomes of a large series of SLE-associated MAS. METHODS We conducted a retrospective study that included 103 episodes of MAS in 89 adult patients with SLE. RESULTS 103 episodes in 89 adult patients were analyzed. Median age at first MAS episode was 32 (18-80) years. MAS was inaugural in 41 patients (46%).Thirteen patients relapsed. Patients had the following features: fever (100% episodes), increased serum levels of AST (94.7%), LDH (92.3%), CRP (84.5%), ferritin (96%), procalcitonin (41/49 cases). Complications included myocarditis (n=22), acute lung injury (n=15) and seizures (n=11). In 33 episodes, patients required hospitalization in an ICU and 5 died. Thrombocytopenia and high CRP levels were associated independently with an increased risk for ICU admission. High dose steroids alone as first line therapy induced remission in 37/57 cases (65%). Additional medications as first or second line therapies included IV immunoglobulins (n=22), cyclophosphamide (n=23), etoposide (n=11), rituximab (n=3). Etoposide and cyclophosphamide-based regimens had the best efficacy. CONCLUSION MAS is a severe complication and is often inaugural. High fever and high levels of AST, LDH, CRP, ferritin and PCT should be considered as red flags for early diagnosis. High dose steroids lead to remission in two third of cases. Cyclophosphamide or etoposide should be considered for uncontrolled/severe forms.


European Radiology | 2018

Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis

Matteo Renzulli; Federica Buonfiglioli; F. Conti; Stefano Brocchi; Ilaria Serio; Francesco Giuseppe Foschi; Paolo Caraceni; G. Mazzella; Gabriella Verucchi; Rita Golfieri; Pietro Andreone; Stefano Brillanti

AbstractObjectivesTo evaluate imaging features of microvascular invasion (MVI) in hepatocellular carcinoma (HCC) developed after direct-acting antiviral (DAA) therapy in HCV-related cirrhosis.MethodsRetrospective cohort study on 344 consecutive patients with HCV-related cirrhosis treated with DAA and followed for 48–74 weeks. Using established imaging criteria for MVI, HCC features were analysed and compared with those in nodules not occurring after DAA.ResultsAfter DAA, HCC developed in 29 patients (single nodule, 18 and multinodular, 11). Median interval between therapy end and HCC diagnosis was 82 days (0–318). Forty-one HCC nodules were detected (14 de novo, 27 recurrent): maximum diameter was 10–20 mm in 27, 20–50 mm in 13, and > 50 mm in 1. Imaging features of MVI were present in 29/41 nodules (70.7%, CI: 54–84), even in 17/29 nodules with 10–20 mm diameter (58.6%, CI: 39–76). MVI was present in only 17/51 HCC nodules that occurred before DAA treatment (33.3%, CI: 22–47) (p= 0.0007). MVI did not correlate with history of previous HCC.ConclusionsHCC occurs rapidly after DAA therapy, and aggressive features of MVI characterise most neoplastic nodules. Close imaging evaluations are needed after DAA in cirrhotic patients.Key Points• In HCV cirrhosis, hepatocellular carcinoma develops soon after direct-acting antiviral therapy. • HCC presents imaging features of microvascular invasion, predictive of more aggressive progression. • Cirrhotic patients need aggressive and close monitoring after direct-acting antiviral therapy.


World Journal of Gastroenterology | 2018

Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis

Simona Leoni; Francesco Tovoli; Lucia Napoli; Ilaria Serio; Silvia Ferri; Luigi Bolondi

The current epidemic of non-alcoholic fatty liver disease (NAFLD) is reshaping the field of hepatology all around the world. The widespread diffusion of metabolic risk factors such as obesity, type2-diabetes mellitus, and dyslipidemia has led to a worldwide diffusion of NAFLD. In parallel to the increased availability of effective anti-viral agents, NAFLD is rapidly becoming the most common cause of chronic liver disease in Western Countries, and a similar trend is expected in Eastern Countries in the next years. This epidemic and its consequences have prompted experts from all over the word in identifying effective strategies for the diagnosis, management, and treatment of NAFLD. Different scientific societies from Europe, America, and Asia-Pacific regions have proposed guidelines based on the most recent evidence about NAFLD. These guidelines are consistent with the key elements in the management of NAFLD, but still, show significant difference about some critical points. We reviewed the current literature in English language to identify the most recent scientific guidelines about NAFLD with the aim to find and critically analyse the main differences. We distinguished guidelines from 5 different scientific societies whose reputation is worldwide recognised and who are representative of the clinical practice in different geographical regions. Differences were noted in: the definition of NAFLD, the opportunity of NAFLD screening in high-risk patients, the non-invasive test proposed for the diagnosis of NAFLD and the identification of NAFLD patients with advanced fibrosis, in the follow-up protocols and, finally, in the treatment strategy (especially in the proposed pharmacological management). These difference have been discussed in the light of the possible evolution of the scenario of NAFLD in the next years.


Digestive and Liver Disease | 2018

Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals

F. Ravaioli; F. Conti; Stefano Brillanti; Pietro Andreone; G. Mazzella; Federica Buonfiglioli; Ilaria Serio; Gabriella Verrucchi; Maria Letizia Bacchi Reggiani; Agostino Colli; Giovanni Marasco; Antonio Colecchia; Davide Festi

BACKGROUND Direct-acting antivirals (DAA) are an effective treatment for hepatitis C virus infection. However, sustained virologic response (SVR) after DAA treatment does not seem to reduce the risk of hepatocellular carcinoma (HCC) development in these patients. Liver stiffness measurement (LSM) may predict the risk of developing HCC in liver cirrhosis patients. AIMS The aim of our study was to evaluate the role of LSM variation as predictor of HCC development in patients treated with DAA. METHODS In 139 HCV-related cirrhotic patients, LSM and laboratory tests were carried out at baseline (BL) and at the end of DAA treatment (EOT). Patients were followed for at least 6 months after the EOT. LSM reduction was expressed as Delta LS (∆LS). Cox regression analysis was used to identify prognostic factors for HCC development after DAA. RESULTS Median LSM values were significantly reduced from BL to EOT (from 18.6 to 13.8 kPa; p < 0.001). The median ∆LS was -26.7% (IQR: -38.4% -13.6%). During a median follow-up of 15 months after DAA treatment, 20 (14.4%) patients developed HCC. Significant LSM reduction was observed both in patients who developed HCC and in those who did not, but this was significantly lower in the patients who developed HCC (-18.0% vs -28.9% p = 0.005). At multivariate analysis, ∆LS lower than -30%, Child-Turcotte-Pugh-B and history of HCC were independently associated with HCC development. CONCLUSION Our results indicate that ∆LS is a useful non-invasive marker for predicting HCC development after DAA treatment.


Hepatic oncology | 2015

Contrast-enhanced ultrasound in liver cancer

Simona Leoni; Ilaria Serio; Anna Pecorelli; Sara Marinelli; Luigi Bolondi

Contrast-enhanced ultrasound (CEUS) is a sure, noninvasive, repeatable imaging technique widely used in the characterization of benign and malignant liver lesions. The European Federation of Societies for Ultrasound in Medicine and Biology guidelines suggest the typical CEUS features of liver lesions as criteria for the noninvasive diagnosis in cirrhotic and not-cirrhotic patients. The clinical application of CEUS in the liver study is summarized in this review; the contrast-enhanced patterns of the most frequent liver lesions are described (hepatocellular and cholangiocellular carcinoma, liver metastases, hemangioma, focal nodular hyperplasia, adenoma). The role of this imaging technique in the diagnostic algorithm of liver malignancy is illustrated and the CEUS application in hepatologic and oncological settings is depicted.


Digestive and Liver Disease | 2014

Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: Experience of the Bologna Liver Oncology Group

Simona Leoni; Fabio Piscaglia; Ilaria Serio; Eleonora Terzi; Irene Pettinari; Luca Croci; Sara Marinelli; Francesca Benevento; Rita Golfieri; Luigi Bolondi


Clinical Rheumatology | 2014

Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review

Ilaria Serio; Laurent Arnaud; Alexis Mathian; Pierre Hausfater; Zahir Amoura


Digestive and Liver Disease | 2018

Corrigendum to “Differences in liver stiffness values obtained with new ultrasound elastography machines and fibroscan: A comparative study” [Dig. Liver Dis. 49 (2017) 802–808]

Fabio Piscaglia; Veronica Salvatore; Lorenzo Mulazzani; Vito Cantisani; Antonio Colecchia; Roberto Di Donato; Cristina Felicani; Alessia Ferrarini; N. Gamal; Valentina Grassoc; Giovanni Marasco; Elena Mazzotta; F. Ravaioli; Giacomo Ruggieri; Ilaria Serio; Joules Fabrice Sitouok Nkamgho; Carla Serra; Davide Festi; Cosima Schiavone; Luigi Bolondi

Collaboration


Dive into the Ilaria Serio's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

F. Conti

University of Bologna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge